Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Common genetic determinants of vitamin D insufficiency: a genome-wide association study.

Lancet (London, England)·2010

Same author

Heart failure and incident late-life depression.

Journal of the American Geriatrics Society·2010

Same author

Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study.

The Journal of clinical endocrinology and metabolism·2010

Same author

Predicting survival and morbidity-free survival to very old age.

Age (Dordrecht, Netherlands)·2010

Same author

Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index.

Annals of the rheumatic diseases·2010

Same author

Paroxysmal disorders in infancy and their risk factors in a population-based cohort: the Generation R Study.

Developmental medicine and child neurology·2010

Search research articles

Related Experiment Video

Updated: May 22, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Antithrombotic medication and incident open-angle glaucoma.

Michael W Marcus¹, Rogier P H M Müskens, Wishal D Ramdas

¹Department of Ophthalmology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Investigative Ophthalmology & Visual Science

|May 17, 2012

Summary

This summary is machine-generated.

Antithrombotic drug use, including anticoagulants and platelet aggregation inhibitors, did not show a significant association with developing open-angle glaucoma (OAG). This study found no increased or decreased risk of OAG in patients using these medications.

Related Experiment Videos

Last Updated: May 22, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Area of Science:

Ophthalmology
Pharmacology
Epidemiology

Background:

Open-angle glaucoma (OAG) is a leading cause of irreversible blindness worldwide.
Antithrombotic drugs are widely prescribed for cardiovascular disease prevention.
The potential impact of antithrombotic medications on glaucoma incidence requires investigation.

Purpose of the Study:

To investigate the association between the use of antithrombotic drugs and the development of incident open-angle glaucoma (OAG).

Main Methods:

Prospective, population-based study (Rotterdam Study) with 3939 participants initially free of OAG.
Ophthalmic examinations, including intraocular pressure (IOP) and perimetry, were conducted at baseline and follow-up.
Continuous monitoring of antithrombotic drug use (anticoagulants and platelet aggregation inhibitors) and adjusted Cox regression analyses were performed.

Main Results:

Over a mean follow-up of 9.8 years, 108 participants (2.7%) developed OAG.
No significant association was found between anticoagulant use (HR 0.90; P=0.69) or platelet aggregation inhibitors (HR 0.80; P=0.28) and incident OAG.
Anticoagulants showed a modest IOP-lowering effect (-0.31 mm Hg; P=0.025), which diminished after adjusting for systemic beta-blocker use.

Conclusions:

Current use of anticoagulants or platelet aggregation inhibitors does not appear to be associated with an increased risk of developing open-angle glaucoma.
The observed IOP-lowering effect of anticoagulants warrants further investigation, particularly concerning confounding factors like concurrent medication use.